| Literature DB >> 30536444 |
Fatma Gargouri1,2, Cécile Gallea1,2,3, Marie Mongin1,2,3,4, Nadya Pyatigorskaya1,2,3,5, Romain Valabregue1,2, Claire Ewenczyk2,3,4, Marie Sarazin6,7, Lydia Yahia-Cherif1,2, Marie Vidailhet2,3,4, Stéphane Lehéricy1,2,3,4.
Abstract
BACKGROUND: Cognitive deficits in Parkinson's disease (PD) may result from damage in the cortex as well as in the dopaminergic, noradrenergic, and cholinergic inputs to the cortex. Cholinergic inputs to the cortex mainly originate from the basal forebrain and are clustered in several regions, called Ch1 to Ch4, that project to the hippocampus (Ch1-2), the olfactory bulb (Ch3), and the cortex and amygdala (Ch4).Entities:
Keywords: acetylcholine; cholinergic; cognition; diffusion MRI; functional connectivity; resting state fMRI
Mesh:
Year: 2018 PMID: 30536444 PMCID: PMC6590238 DOI: 10.1002/mds.27561
Source DB: PubMed Journal: Mov Disord ISSN: 0885-3185 Impact factor: 10.338
Demographical, clinical, and neuropsychological data
| Data | HV | PD |
| |
|---|---|---|---|---|
|
| ||||
| Number of subjects | 25 | 52 | ||
| Males/females | 13/12 | 37/15 | .05 | |
| Age, y | 59.8 ± 8.0 | 60.6 ± 8.8 | .71 | |
| Disease duration | – | 8.7 ± 3.5 | ||
| Education | 5.68 ± 1.49 | 5.19 ± 1.55 | .19 | |
|
| ||||
| Hoehn and Yahr stage, 0–5 | – | 1.88 ± 0.63 | ||
| UPDRS III (“best‐on” condition), 0–108 | 0.6 ± 0.1 | 16.4 ± 8.8 |
| |
| Levodopa equivalent daily dose (mg) | – | 786.7 ± 290.62 | ||
|
| ||||
| Mattis Dementia Rating Scale, 0–144 | 140.0 ± 2.6 | 136.0 ± 9.4 | .12 | |
| Mini‐Mental State Evaluation, 0–30 | 28.7 ± 1.1 | 27.8 ± 1.8 |
| |
| Montgomery Asberg Depression Rating Scale | 4.32 ± 4.25 | 9.00 ± 5.47 |
| |
| Epworth scale | 4.52 ± 3.00 | 8.73 ± 5.07 |
| |
|
| ||||
| Immediate free recall/16 | 15.6 ± 0.7 | 14.5 ± 1.7 |
| |
| Total free recall/48 | 33.1 ± 4.9 | 28.2 ± 6.8 |
| |
| Total recall/48 | 47.2 ± 1.4 | 45.2 ± 3.1 |
| |
| Delayed free recall/16 | 12.5 ± 2.1 | 11.1 ± 3.2 |
| |
| Delayed total recall/16 | 15.8 ± 0.6 | 15.4 ± 1.1 | .05 | |
|
| ||||
| Code | 67.8 ± 13.7 | 51.6 ± 13.5 |
| |
| Letter number | 9.8 ± 3.4 | 8.5 ± 3.0 | .07 | |
| Trail‐Making Test B‐A | 43.3 ± 32.6 | 55.9 ± 35.4 | .12 | |
|
| ||||
| Denomination | 76.2 ± 15.0 | 66.4 ± 10.6 |
| |
| Reading | 99.5 ± 14.5 | 92.1 ± 14.7 |
| |
| Interference | 40.0 ± 6.1 | 35.5 ± 9.8 |
| |
|
| ||||
| Recall | 34.9 ± 1.3 | 34.1 ± 2.5 | .14 | |
| Copy | 18.4 ± 4.5 | 19.7 ± 4.9 | .63 | |
Significant P values are indicated in bold. Chi2, chi‐squared test; HV, healthy volunteer; UPDRS, Unified Parkinson's Disease Rating Scale; WAIS, Wechsler Adult Intelligence Scale.
Groups were compared using t‐tests except Chi2.
Figure 1MRI‐based segmentation of Ch1‐Ch4. (A) Coronal view of Ch1‐2 (purple) and Ch3‐4 (light blue) regions of interest superimposed on coronal T1‐weighted Montreal Neurological Institute template image. (B) Three‐dimensional representation of the regions of interest on a multiplanar view of the Montreal Neurological Institute template, (C) Fornix tractography between Ch1‐2 and the hippocampi, and (D) Freesurfer segmentation of the cortical and subcortical areas.
Diffusion changes in the basal forebrain and fornix
| Region | Diffusion measure | Healthy volunteers | PD patients | ANCOVA |
|---|---|---|---|---|
| Fornix | FA | 0.213 ± 0.036 | 0.212 ± 0.037 | .527 |
| MD | 0.961 ± 0.086 | 1.025 ± 0.109 | .077 | |
| AD | 1.151 ± 0.089 | 1.214 ± 0.105 |
| |
| RD | 0.870 ± 0.085 | 0.924 ± 0.113 | .151 | |
| Ch1‐2 | FA | 0.171 ± 0.022 | 0.168 ± 0.021 | .876 |
| MD | 0.796 ± 0.080 | 0.853 ± 0.081 |
| |
| AD | 0.915 ± 0.091 | 0.977 ± 0.080 |
| |
| RD | 0.737 ± 0.076 | 0.790 ± 0.081 |
| |
| Ch3‐4 | FA | 0.210 ± 0.026 | 0.202 ± 0.025 | 367 |
| MD | 0.744 ± 0.089 | 0.805 ± 0.082 |
| |
| AD | 0.875 ± 0.103 | 0.948 ± 0.083 | .053 | |
| RD | 0.678 ± 0.083 | 0.735 ± 0.084 |
|
Values are in mm.s−2 × 10−3. Significant differences are indicated in bold. AD, axial diffusivity; ANCOVA, analysis of covariance; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity.
Figure 2Results of the functional connectivity analysis. PD patients showed reduced functional connectivity (A) between Ch1‐2 and the hippocampus, the parahippocampal gyrus, the middle and superior temporal gyri and the fusiform gyrus, and (B) between Ch3‐4 and the inferior frontal and the thalamus. Cluster significant at P < .05, family wise error corrected for multiple comparisons, left is left. C shows the contrast estimates for Ch1‐2–hippocampus connectivity and D shows the contrast estimates for Ch3‐4–inferior frontal area connectivity, respectively. HV, healthy volunteers; L, left; MTG, middle temporal gyrus; STG, superior temporal gyrus; PD, Parkinson's disease; PHG, parahippocampal gyrus; R, right.
Figure 3Correlations between clinical scores and imaging measures. (A) Radial diffusivity (RD) in Ch1‐2 correlated with scores at the total free recall (TFR) and (D) radial diffusivity in Ch3‐4 correlated with scores at the Stroop denomination test. (B) Functional connectivity changes in Ch1‐2 correlated with scores at the immediate cued recall (ICR) in the hippocampus. (C) There was a correlation trend for total free recall (TFR) in the superior frontal gyrus. (E) Functional connectivity changes in Ch3‐4 correlated with scores at the Stroop denomination test in the superior parietal cortex and (F) at the MMSE in the middle frontal gyrus. ICR, immediate cued recall; MMSE, mini mental status examination; RD, radial diffusivity; TFR, total free recall.